ethylsulfonyl-methylcyclohexane | 52075-27-1

• 分子结构分类: 有机化合物 - 有机硫化合物 - 磺酰类
• 英文名称: ethylsulfonyl-methylcyclohexane
• 英文别名: Ethylsulfonylmethylcyclohexane
• CAS: 52075-27-1
• 化学式: C₉H₁₈O₂S
• 分子量: 190.307
• InChiKey: JTXNTPDAMKYHNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  bromomethanesulfonyl-ethane 、 三环己基硼烷 在 potassium tert-butylate 作用下， 以 叔丁醇 为溶剂， 生成 ethylsulfonyl-methylcyclohexane
  参考文献：
  名称：

  Alkylation of .alpha.-bromosulfonyl compounds with trialkylboranes

  摘要：

  DOI：

  10.1021/jo00926a038

文献信息

• Novel Compounds and Compositions as Cathepsin Inhibitors
  申请人：Patterson W. John

  公开号：US20070232654A1

  公开（公告）日：2007-10-04

  The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

  本发明涉及新型选择性卡特普西林S抑制剂，其药学上可接受的盐和N-氧化物，以及它们作为治疗剂的用途和制备方法。
• Novel compounds and compositions as cathepsin inhibitors
  申请人：Graupe Michael

  公开号：US20070049594A1

  公开（公告）日：2007-03-01

  The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

  本发明涉及一种新型选择性卡普林S抑制剂，其药物可接受的盐和N-氧化物，以及它们作为治疗剂的用途和制备方法。
• HETERO RING DERIVATIVE
  申请人：Takahashi Fumie

  公开号：US20120165309A1

  公开（公告）日：2012-06-28

  [Object] A novel and excellent method for preventing or treating rejection in the transplantation of various organs, allergy diseases, autoimmune diseases, hematologic tumor, or the like, based on a PI3Kδ-selective inhibitory action and/or an IL-2 production inhibitory action, and/or a B cell proliferation inhibitory action (including an activation inhibitory action), is provided [Means for Solution] It was found that a 3-substituted triazine or 3-substituted pyrimidine derivative exhibits a PI3Kδ-selective inhibitory action, and/or an IL-2 production inhibitory action, and/or a B cell proliferation inhibitory action (including an activation inhibitory action), and can be an agent for preventing or treating rejection in the transplantation of various organs, allergy diseases (asthma, atopic dermatitis, etc.), autoimmune diseases (rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, etc.), hematologic tumor (leukemia etc.), or the like, thereby completing the present invention.

  [目标]提供一种基于PI3Kδ选择性抑制作用和/或IL-2产生抑制作用和/或B细胞增殖抑制作用（包括激活抑制作用）的新颖优良方法，用于预防或治疗各种器官移植、过敏性疾病、自身免疫性疾病、血液肿瘤等的排斥反应。 [解决方案]发现3-取代-1,3,5-三嗪或3-取代嘧啶衍生物表现出PI3Kδ选择性抑制作用和/或IL-2产生抑制作用和/或B细胞增殖抑制作用（包括激活抑制作用），可以作为预防或治疗各种器官移植、过敏性疾病（哮喘、特应性皮炎等）、自身免疫性疾病（类风湿性关节炎、银屑病、溃疡性结肠炎、克罗恩病、系统性红斑狼疮等）、血液肿瘤（白血病等）等排斥反应的药物，从而完成了本发明。
• Alkylation of .alpha.-bromosulfonyl compounds with trialkylboranes
  作者：William E. Truce、Lawrence A. Mura、Peter J. Smith、Fred Young

  DOI：10.1021/jo00926a038

  日期：1974.5